7th Targeted Radiopharmaceuticals Summit Europe

10–12 November 2025 | Amsterdam

Translating Novel Radiopharmaceutical Therapies to Transform the Medical Future

Now in its seventh year, the Targeted Radiopharmaceuticals Summit Europe returns to Amsterdam to bring together over 200 leaders in radiopharmaceutical therapy development. Designed to establish radiopharmaceuticals as a core pillar of oncology, this event is essential for professionals working across discovery, clinical development, and manufacturing.

Highlights of the 2025 Program:

More than 45 expert speakers from leading companies including Bayer, AstraZeneca, Novartis, Telix Pharmaceuticals, and more
Introduction of a third content track, covering:
Discovery & Preclinical
Translational & Clinical
CMC & Sourcing
Six in-depth workshops on key challenges including radiopharmaceutical design, dosimetry translation, and isotope supply

Key Speakers:

Thomas Birger Eden-Jensen, Head, External Supply Management TRP, Bayer
Mark Fielding, Director, CMC, Regulatory Affairs, TRP, AstraZeneca NEW SPEAKER
Isabel Jaco, Group Leader, RLT Drug Discovery, Novartis NEW SPEAKER
Sandra Uhlenbroich, Director, Discovery, Bicycle Therapeutics NEW SPEAKER
Frederic Fantino, Global Medical Affairs EMEA, Telix Pharmaceuticals NEW SPEAKER
Thijs Spoor, Chief Executive Officer, Perspective Therapeutics NEW SPEAKER
Sigal Kalmanson, Chief Executive Officer, Starget Pharma

Topics Include:

Novel target discovery, including SSTR3 and FAP
Isotope selection and supply chain resilience
Translating dosimetry into clinical studies
First-in-human study design and Phase 0 considerations
Scalable and compliant manufacturing strategies

This is the most comprehensive European agenda for targeted radiopharmaceuticals to date, built to accelerate asset development and address the sector’s most pressing challenges.

View the full program: https://ter.li/gowcuf

Hyperlink – https://ter.li/gowcuf